Venezuela (Bolivarian Republic of)

Venezuela (Bolivarian Republic of)

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.73 (0.58 - 0.89) 2019 Modelled IHME
0.72 (0.59 - 0.86) 2018 Modelled IHME
0.72 (0.59 - 0.86) 2017 Modelled IHME
0.73 (0.60 - 0.87) 2016 Modelled IHME
0.75 (0.61 - 0.90) 2015 Modelled IHME
0.77 (0.63 - 0.91) 2014 Modelled IHME
0.78 (0.64 - 0.93) 2013 Modelled IHME
0.79 (0.65 - 0.95) 2012 Modelled IHME
0.81 (0.65 - 0.97) 2011 Modelled IHME
0.82 (0.67 - 1) 2010 Modelled IHME
0.84 (0.67 - 1) 2009 Modelled IHME
0.85 (0.69 - 1.02) 2008 Modelled IHME
0.87 (0.71 - 1.03) 2007 Modelled IHME
0.89 (0.72 - 1.05) 2006 Modelled IHME
0.89 (0.72 - 1.06) 2005 Modelled IHME
0.89 (0.72 - 1.06) 2004 Modelled IHME
0.89 (0.72 - 1.07) 2003 Modelled IHME
0.89 (0.71 - 1.08) 2002 Modelled IHME
0.89 (0.71 - 1.09) 2001 Modelled IHME
0.89 (0.71 - 1.09) 2000 Modelled IHME
0.89 (0.70 - 1.08) 1999 Modelled IHME
0.89 (0.70 - 1.07) 1998 Modelled IHME
0.88 (0.70 - 1.06) 1997 Modelled IHME
0.87 (0.70 - 1.06) 1996 Modelled IHME
0.87 (0.70 - 1.06) 1995 Modelled IHME
0.87 (0.70 - 1.06) 1994 Modelled IHME
0.88 (0.71 - 1.06) 1993 Modelled IHME
0.89 (0.71 - 1.08) 1992 Modelled IHME
0.9 (0.73 - 1.10) 1991 Modelled IHME
0.92 (0.74 - 1.13) 1990 Modelled IHME
3.2 (1.70 - 4.70) 1999 Survey/reported Silveira TR et al, 1999
2.83 (2.12 - 3.85) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.15 (0.10 - 0.20) 2019 Modelled IHME
0.14 (0.10 - 0.19) 2018 Modelled IHME
0.14 (0.09 - 0.19) 2017 Modelled IHME
0.14 (0.10 - 0.19) 2016 Modelled IHME
0.15 (0.10 - 0.20) 2015 Modelled IHME
0.16 (0.11 - 0.21) 2014 Modelled IHME
0.16 (0.11 - 0.22) 2013 Modelled IHME
0.17 (0.12 - 0.23) 2012 Modelled IHME
0.18 (0.12 - 0.24) 2011 Modelled IHME
0.18 (0.13 - 0.25) 2010 Modelled IHME
0.19 (0.13 - 0.25) 2009 Modelled IHME
0.19 (0.13 - 0.25) 2008 Modelled IHME
0.19 (0.13 - 0.25) 2007 Modelled IHME
0.19 (0.13 - 0.26) 2006 Modelled IHME
0.2 (0.14 - 0.26) 2005 Modelled IHME
0.22 (0.16 - 0.30) 2004 Modelled IHME
0.27 (0.19 - 0.37) 2003 Modelled IHME
0.33 (0.23 - 0.46) 2002 Modelled IHME
0.39 (0.27 - 0.55) 2001 Modelled IHME
0.42 (0.29 - 0.60) 2000 Modelled IHME
0.44 (0.30 - 0.60) 1999 Modelled IHME
0.45 (0.31 - 0.61) 1998 Modelled IHME
0.46 (0.31 - 0.62) 1997 Modelled IHME
0.47 (0.32 - 0.64) 1996 Modelled IHME
0.48 (0.32 - 0.65) 1995 Modelled IHME
0.49 (0.33 - 0.66) 1994 Modelled IHME
0.49 (0.34 - 0.66) 1993 Modelled IHME
0.5 (0.35 - 0.67) 1992 Modelled IHME
0.51 (0.36 - 0.68) 1991 Modelled IHME
0.51 (0.36 - 0.70) 1990 Modelled IHME
0.62 (0.41 - 0.91) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
15 (10 - 21) 2019 Modelled IHME
15 (11 - 22) 2018 Modelled IHME
15 (11 - 22) 2017 Modelled IHME
15 (11 - 22) 2016 Modelled IHME
15 (11 - 21) 2015 Modelled IHME
15 (11 - 21) 2014 Modelled IHME
15 (11 - 22) 2013 Modelled IHME
16 (11 - 22) 2012 Modelled IHME
16 (11 - 22) 2011 Modelled IHME
16 (11 - 22) 2010 Modelled IHME
16 (11 - 22) 2009 Modelled IHME
16 (12 - 23) 2008 Modelled IHME
16 (12 - 23) 2007 Modelled IHME
16 (12 - 23) 2006 Modelled IHME
16 (12 - 23) 2005 Modelled IHME
16 (12 - 23) 2004 Modelled IHME
17 (12 - 23) 2003 Modelled IHME
17 (12 - 23) 2002 Modelled IHME
17 (12 - 23) 2001 Modelled IHME
17 (12 - 23) 2000 Modelled IHME
17 (12 - 23) 1999 Modelled IHME
17 (12 - 23) 1998 Modelled IHME
17 (12 - 23) 1997 Modelled IHME
17 (12 - 23) 1996 Modelled IHME
17 (12 - 23) 1995 Modelled IHME
17 (12 - 23) 1994 Modelled IHME
17 (12 - 23) 1993 Modelled IHME
17 (12 - 23) 1992 Modelled IHME
17 (12 - 23) 1991 Modelled IHME
17 (12 - 23) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
55 2018 Survey/reported WHO/UNICEF
56 2017 Survey/reported WHO/UNICEF
56 2016 Survey/reported WHO/UNICEF
64 2015 Survey/reported WHO/UNICEF
72 2014 Survey/reported WHO/UNICEF
80 2013 Survey/reported WHO/UNICEF
67 2012 Survey/reported WHO/UNICEF
78 2011 Survey/reported WHO/UNICEF
73 2010 Survey/reported WHO/UNICEF
66 2009 Survey/reported WHO/UNICEF
73 2008 Survey/reported WHO/UNICEF
64 2007 Survey/reported WHO/UNICEF
61 2006 Survey/reported WHO/UNICEF
63 2005 Survey/reported WHO/UNICEF
57 2004 Survey/reported WHO/UNICEF
44 2003 Survey/reported WHO/UNICEF
34 2002 Survey/reported WHO/UNICEF
35 2001 Survey/reported WHO/UNICEF
14 2000 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
60 2018 Survey/reported WHO/UNICEF
66 2017 Survey/reported WHO/UNICEF
84 2016 Survey/reported WHO/UNICEF
87 2015 Survey/reported WHO/UNICEF
78 2014 Survey/reported WHO/UNICEF
82 2013 Survey/reported WHO/UNICEF
81 2012 Survey/reported WHO/UNICEF
78 2011 Survey/reported WHO/UNICEF
78 2010 Survey/reported WHO/UNICEF
84 2009 Survey/reported WHO/UNICEF
53 2008 Survey/reported WHO/UNICEF
62 2007 Survey/reported WHO/UNICEF
71 2006 Survey/reported WHO/UNICEF
88 2005 Survey/reported WHO/UNICEF
82 2004 Survey/reported WHO/UNICEF
72 2003 Survey/reported WHO/UNICEF
60 2002 Survey/reported WHO/UNICEF
53 2001 Survey/reported WHO/UNICEF
5 2000 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
2003
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
Yes
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.91 (1.54 - 2.37) 2019 Modelled IHME
1.91 (1.54 - 2.36) 2018 Modelled IHME
1.89 (1.54 - 2.36) 2017 Modelled IHME
1.84 (1.49 - 2.26) 2016 Modelled IHME
1.78 (1.43 - 2.19) 2015 Modelled IHME
1.76 (1.42 - 2.16) 2014 Modelled IHME
1.74 (1.40 - 2.15) 2013 Modelled IHME
1.72 (1.38 - 2.14) 2012 Modelled IHME
1.71 (1.37 - 2.13) 2011 Modelled IHME
1.71 (1.37 - 2.13) 2010 Modelled IHME
1.74 (1.42 - 2.12) 2009 Modelled IHME
1.81 (1.52 - 2.15) 2008 Modelled IHME
1.9 (1.63 - 2.21) 2007 Modelled IHME
1.98 (1.72 - 2.27) 2006 Modelled IHME
2.01 (1.75 - 2.30) 2005 Modelled IHME
1.99 (1.73 - 2.28) 2004 Modelled IHME
1.93 (1.68 - 2.21) 2003 Modelled IHME
1.87 (1.63 - 2.14) 2002 Modelled IHME
1.81 (1.58 - 2.07) 2001 Modelled IHME
1.79 (1.56 - 2.05) 2000 Modelled IHME
1.81 (1.57 - 2.07) 1999 Modelled IHME
1.85 (1.61 - 2.12) 1998 Modelled IHME
1.89 (1.63 - 2.18) 1997 Modelled IHME
1.93 (1.66 - 2.23) 1996 Modelled IHME
1.95 (1.67 - 2.25) 1995 Modelled IHME
1.94 (1.67 - 2.25) 1994 Modelled IHME
1.93 (1.64 - 2.24) 1993 Modelled IHME
1.89 (1.60 - 2.22) 1992 Modelled IHME
1.85 (1.53 - 2.23) 1991 Modelled IHME
1.8 (1.44 - 2.23) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.5 (0.30 - 2.60) 2014 Modelled Gower et al, 2014

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
36 (27 - 46) 2019 Modelled IHME
36 (27 - 45) 2018 Modelled IHME
36 (27 - 45) 2017 Modelled IHME
36 (27 - 45) 2016 Modelled IHME
36 (27 - 45) 2015 Modelled IHME
36 (27 - 44) 2014 Modelled IHME
35 (26 - 44) 2013 Modelled IHME
35 (26 - 43) 2012 Modelled IHME
35 (26 - 43) 2011 Modelled IHME
35 (26 - 43) 2010 Modelled IHME
34 (26 - 43) 2009 Modelled IHME
34 (26 - 43) 2008 Modelled IHME
34 (26 - 43) 2007 Modelled IHME
34 (26 - 43) 2006 Modelled IHME
35 (26 - 43) 2005 Modelled IHME
35 (26 - 44) 2004 Modelled IHME
35 (26 - 44) 2003 Modelled IHME
35 (27 - 44) 2002 Modelled IHME
35 (26 - 44) 2001 Modelled IHME
35 (26 - 44) 2000 Modelled IHME
35 (27 - 44) 1999 Modelled IHME
35 (26 - 44) 1998 Modelled IHME
35 (27 - 44) 1997 Modelled IHME
35 (26 - 44) 1996 Modelled IHME
35 (26 - 44) 1995 Modelled IHME
35 (27 - 45) 1994 Modelled IHME
35 (27 - 44) 1993 Modelled IHME
36 (27 - 44) 1992 Modelled IHME
36 (27 - 45) 1991 Modelled IHME
36 (27 - 45) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
2003
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
Yes
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.73 (%)
2019
(0.58 - 0.89(%))
IHME
HCV (RNA/cAg+)
1.91 (%)
2019
(1.54 - 2.37(%))
IHME

Survey/surveillance

HBV (HBsAg+)
3.2 (%)
1999
(1.7 - 4.7(%))
Silveira TR et al, 1999
No data available

Hepatitis related deaths (national)

Modelled

HBV
283
2019
(190 - 407)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
1,407
2019
(941 - 2,004)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.15 (%)
2019, latest modelled
(0.10 - 0.20(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
55 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines
Yes